January 13, 2017

January 13, 2017

Trump criticism leads to falling stock prices at these Tampa employers
Tampa Bay Business Journal – Jan. 12
Lion Biotechnologies Inc. (NASDAQ: LBIO), a biotech company focused on cancer immunotherapy, was down 1.37 percent. Lion partners with Moffitt Cancer Center and leases space in University of South Florida Research Park in Tampa.

Moffitt Researchers Developing Vaccine To Fight Breast Cancer
WLRN – Jan. 12
Researchers at Tampa's Moffitt Cancer Center are testing a vaccine to fight breast cancer,  and they say  that it appears to be working for some patients.

MDS: When the Prognostic Models Fall Short
OncLive – Jan. 12
Rami S. Komrokji, MD: Right. I think we know that transfusion dependency is not a good player in MDS. If you look at all MDS patients, I think 90% or more, they will have anemia, and maybe 60% to 70% at one point will become transfusion dependent.

HER2 Vaccine Shows Promise in Early-Stage Breast Cancer
OncLive – Jan. 12
“In this study, we compared where we injected them, and it didn’t seem to make any difference as far as either inducing an immune response or causing regression of the tumors,” said lead study author Brian J. Czerniecki, MD, PhD.

Novel treatment can effectively inhibit development of GVHD in mice, study shows
News Medical – Jan. 12
Graft-versus-host-disease (GVHD) is the leading cause of non-relapse associated death in patients who receive stem cell transplants. In a new study published as the cover story in Science Translational Medicine, Moffitt Cancer Center researchers show that a novel treatment can effectively inhibit the development of GVHD in mice and maintain the infection- and tumor-fighting capabilities of the immune system.

New drug shows improved progression-free survival for patients with advanced metastatic midgut neuroendocrine tumors
Medical Xpress – Jan. 12
"Patients diagnosed with midgut neuroendocrine tumors often have advanced disease that has spread to other sites. Treatment options are limited. 177Lu-Dotatate is an effective option to delay tumor progression for patients with this disease," says Jonathan R. Strosberg, head of the Neuroendocrine Tumor Program at Moffitt Cancer Center.

Impressive Results With Radiopharmaceutical in NET Confirmed
Medscape – Jan. 11
The final results, now reported by Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, Tampa, Florida, and colleagues, show that Lu-Dotatate achieved a clinically meaningful reduction in the risk for disease progression or death compared with standard care of almost 80%, and more than tripled the response rate compared with previous trials of other therapies.

Dr. Soliman on Impact of MammaPrint in Patients With Early-Stage Breast Cancer
OncLive – Jan. 11
Hatem Soliman, MD, associate member of The Center for Women’s Oncology at the Moffitt Cancer Center discusses the prospective registry IMPACt study, which measured the impact of the MammaPrint 70-gene Breast Cancer Recurrence Assay in the routine management of women with early-stage breast cancer.

Accurate Risk Assessment in MDS
OncLive – Jan. 11
Rami S. Komrokji, MD: I think this is a principle that we use in oncology in general. I always teach the Fellows the first step, you want to make sure the diagnosis is made right. And in MDS, we all know that could be the most challenging.

Less Than Half the Children in the U.S. Have Had HPV Vaccine; Doctors Strongly Urge Increase
Yahoo Beauty – Jan. 11
Susan Vadaparampil, MD, MPH, of Moffitt Cancer Center, tells Yahoo Beauty that there are likely several reasons for the low vaccination rates. Pediatricians may not be recommending the vaccine to patients and their parents as strongly as they should, she says. “Provider recommendation is a very important aspect of parents deciding to choose a medical treatment or preventive strategy for their child,” she says. “We see that providers do not consistently or strongly recommend the vaccine.”

Researchers develop novel treatment to prevent graft-versus-host-disease
Medical Xpress – Jan. 11
Graft-versus-host-disease (GVHD) is the leading cause of non-relapse associated death in patients who receive stem cell transplants. In a new study published as the cover story in Science Translational Medicine, Moffitt Cancer Center researchers show that a novel treatment can effectively inhibit the development of GVHD in mice and maintain the infection- and tumor-fighting capabilities of the immune system.

Moffitt exec steps into state, national leadership roles
Tampa Bay Business Journal – Jan. 10
Talk about a full plate. Jack Kolosky, president of Moffitt Cancer Center Hospital and a corporate executive vice president, has taken on two new leadership roles outside the cancer center in 2017.

Fosun, Daiichi Sankyo Ink Deals for Kite's CAR-T Cell Therapy in China and Japan
Genetic Engineering & Biotechnology News – Jan. 10
Earlier this month Moffitt Cancer Center researchers reported promising data from the Phase I stage of the ZUMA-1 trial evaluating KTE-C19 in the treatment of B-cell lymphoma.

New CAR T-cell Therapy Shows ‘Remarkable’ Promise for Highly Refractory Lymphoma
Lymphoma News Today – Jan. 9
Frederick L. Locke, MD, director of Research for the Moffitt Cancer Center Immune Cell Therapy Clinical Trial Group, said in a news release.

Kathy Castor calls GOP not to repeal ACA without a viable replacement
FloridaPolitics.com – Jan. 9
Greg Robinson was diagnosed with a very aggressive form of blood cancer in October of 2015, and underwent extensive chemotherapy and a stem cell transplant to “essentially save my life” at Moffitt Cancer Center.He’s always been able to receive insurance through his employer,  but he says that the thought of his insurer no longer having to carry a patient with pre-existing conditions – a key tenet of the ACA- is something he calls “terrifying.”

Ofrecen programas especiales para personas sin seguro médico (Video)
Mundo Hispanico –Jan. 9
Que los hombres estén libres de cáncer, es uno de los obejtivos de Moffit Cancer Center Tampa, la organización que trabaja en el cuidado de pacientes a través de la investigación y la educación en la lucha contra este mal que acaba con la vida de miles de personas.

Business People
Sarasota Herald Tribune – Jan. 9
Before joining Sarasota Memorial's First Physicians Group in 2005, Fiorica was the program leader of the Gynecology Oncology Program at Moffitt Cancer Center and Research Institute, in Tampa.

New Year's Exercise Tips for Cancer Patients
Tap Into – Jan. 8
Located in Tampa, Florida, Moffitt Cancer Center is one of the top cancer treatment centers in the United States.

This New Breast Cancer Treatment Won't Have Nasty Side Effects
Female Network - Jan. 7
"Researchers from Moffitt Cancer Center in Tampa, Florida are developing a new treatment for breast cancer in the form of an 'immunology vaccine' that enhances your immune system, allowing your body to use its best weapon to kill those cancer cells," reports Shape.com.

Mark Sharpe: The key to growing Tampa Bay's economy
Tampa Bay Times – Jan. 6
Our challenge is to connect the Alliance anchors together into a recognized innovation destination that leverages the power of USF, Moffitt and our other partners into a high-tech job-generating machine. A doubling of STEM jobs in the Alliance area would propel Hillsborough County and Tampa Bay as a recognized technology hub, creating the very jobs necessary to lift median wages and help us move from 33rd into the top 10.

Editorial: Amazon, Macy's tell the story of Hillsborough's changing commerce
Tampa Bay Times – Jan. 6
But beyond even the retail experiences, those helping shape the future of University Mall are looking at other development that would cater to medical tourism and research industries — vital in an area that's home to Moffitt Cancer Center, Florida Hospital Tampa and James A. Haley VA Medical Center.

CAR T-Cell Therapy for Lymphoma Leads to Complete Remission in Phase I Trial
Genetic Engineering and Biotechnology News – Jan. 6
Immunotherapy approaches for treating cancer continue to exceed expectations by providing novel, highly efficient treatment options. Adding another potential success to the immunotherapy toolbox, investigators from the Moffitt Cancer Center just released promising results from the Phase I portion of the ZUMA-1 study, which uses chimeric antigen receptor (CAR)-modified T cells to treat B-cell lymphoma patients.


Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.